Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase I/II Ready [Yahoo! Finance]
Molecular Partners AG - American Depositary Shares (MOLN)
Company Research
Source: Yahoo! Finance
lesions demonstrated increasing uptake and strong retention with low healthy-organ (liver/kidney) background. Dosimetry estimates suggest projected therapeutic use of Lead-212 at an initial 1×75 MBq dose would keep absorbed doses to the kidneys and red marrow within external-beam radiation reference limits, supporting planned hematologic monitoring and the possibility of repeat dosing. The U.S. phase I/II trial is open and ready for screening with initial patients expected soon; Molecular Partners is collaborating with Orano Med using Lead-203 for imaging and Lead-212 for therapy (with Actinium-225 discussed as a potential future option) and plans safety updates in H1 and early activity readouts in H2 2026. Interested in Molecular Partners AG Sponsored ADR? Here are five stocks we like better. Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy Molecular Partners (NASDAQ:MOLN) hosted a webcast to discuss clinical imaging and dosimetry data for MP0712, its DLL3-targe
Show less
Read more
Impact Snapshot
Event Time:
MOLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MOLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MOLN alerts
High impacting Molecular Partners AG - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
MOLN
News
- Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript [Seeking Alpha]Seeking Alpha
- Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026 [Yahoo! Finance]Yahoo! Finance
- Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026GlobeNewswire
- Molecular Partners (NASDAQ:MOLN) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.MarketBeat
- Molecular Partners (NASDAQ:MOLN) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.MarketBeat
MOLN
Sec Filings
- 2/2/26 - Form 6-K
- 1/12/26 - Form 6-K
- 12/8/25 - Form 6-K
- MOLN's page on the SEC website